These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36517170)

  • 21. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
    Mackenzie IS; Hawkey CJ; Ford I; Greenlaw N; Pigazzani F; Rogers A; Struthers AD; Begg AG; Wei L; Avery AJ; Taggar JS; Walker A; Duce SL; Barr RJ; Dumbleton JS; Rooke ED; Townend JN; Ritchie LD; MacDonald TM;
    Lancet; 2022 Oct; 400(10359):1195-1205. PubMed ID: 36216006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.
    Kirchhof P; Toennis T; Goette A; Camm AJ; Diener HC; Becher N; Bertaglia E; Blomstrom Lundqvist C; Borlich M; Brandes A; Cabanelas N; Calvert M; Chlouverakis G; Dan GA; de Groot JR; Dichtl W; Kravchuk B; Lubiński A; Marijon E; Merkely B; Mont L; Ozga AK; Rajappan K; Sarkozy A; Scherr D; Sznajder R; Velchev V; Wichterle D; Sehner S; Simantirakis E; Lip GYH; Vardas P; Schotten U; Zapf A; ;
    N Engl J Med; 2023 Sep; 389(13):1167-1179. PubMed ID: 37622677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial.
    Schreuder FHBM; van Nieuwenhuizen KM; Hofmeijer J; Vermeer SE; Kerkhoff H; Zock E; Luijckx GJ; Messchendorp GP; van Tuijl J; Bienfait HP; Booij SJ; van den Wijngaard IR; Remmers MJM; Schreuder AHCML; Dippel DW; Staals J; Brouwers PJAM; Wermer MJH; Coutinho JM; Kwa VIH; van Gelder IC; Schutgens REG; Zweedijk B; Algra A; van Dalen JW; Jaap Kappelle L; Rinkel GJE; van der Worp HB; Klijn CJM;
    Lancet Neurol; 2021 Nov; 20(11):907-916. PubMed ID: 34687635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial.
    Metzner A; Suling A; Brandes A; Breithardt G; Camm AJ; Crijns HJGM; Eckardt L; Elvan A; Goette A; Haegeli LM; Heidbuchel H; Kautzner J; Kuck KH; Mont L; Ng GA; Szumowski L; Themistoclakis S; van Gelder IC; Vardas P; Wegscheider K; Willems S; Kirchhof P
    Europace; 2022 Apr; 24(4):552-564. PubMed ID: 34473249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry.
    Proietti M; Vitolo M; Harrison SL; Lane DA; Fauchier L; Marin F; Nabauer M; Potpara TS; Dan GA; Boriani G; Lip GYH;
    Clin Res Cardiol; 2022 Jan; 111(1):70-84. PubMed ID: 34448931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial.
    Svendsen JH; Diederichsen SZ; Højberg S; Krieger DW; Graff C; Kronborg C; Olesen MS; Nielsen JB; Holst AG; Brandes A; Haugan KJ; Køber L
    Lancet; 2021 Oct; 398(10310):1507-1516. PubMed ID: 34469766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world evidence of early rhythm control in patients with atrial fibrillation: A systematic review and meta-analysis.
    Gu Z; Guo L; Liu C; Lip GYH; Zhu W
    Int J Cardiol; 2024 Oct; 412():132327. PubMed ID: 38964555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic yield of a proactive strategy for early detection of cardiovascular disease versus usual care in adults with type 2 diabetes or chronic obstructive pulmonary disease in primary care in the Netherlands (RED-CVD): a multicentre, pragmatic, cluster-randomised, controlled trial.
    Groenewegen A; Zwartkruis VW; Rienstra M; Zuithoff NPA; Hollander M; Koffijberg H; Oude Wolcherink M; Cramer MJ; van der Schouw YT; Hoes AW; Rutten FH; de Boer RA
    Lancet Public Health; 2024 Feb; 9(2):e88-e99. PubMed ID: 38134944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.
    Kelly P; Lemmens R; Weimar C; Walsh C; Purroy F; Barber M; Collins R; Cronin S; Czlonkowska A; Desfontaines P; De Pauw A; Evans NR; Fischer U; Fonseca C; Forbes J; Hill MD; Jatuzis D; Kõrv J; Kraft P; Kruuse C; Lynch C; McCabe D; Mikulik R; Murphy S; Nederkoorn P; O'Donnell M; Sandercock P; Schroeder B; Shim G; Tobin K; Williams DJ; Price C
    Lancet; 2024 Jul; 404(10448):125-133. PubMed ID: 38857611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
    Kirchhof P; Blank BF; Calvert M; Camm AJ; Chlouverakis G; Diener HC; Goette A; Huening A; Lip GYH; Simantirakis E; Vardas P
    Am Heart J; 2017 Aug; 190():12-18. PubMed ID: 28760205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial.
    Svennberg E; Friberg L; Frykman V; Al-Khalili F; Engdahl J; Rosenqvist M
    Lancet; 2021 Oct; 398(10310):1498-1506. PubMed ID: 34469764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial.
    Yao Y; Guo Y; Lip GYH;
    JAMA Netw Open; 2021 Dec; 4(12):e2140071. PubMed ID: 34932104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of Early Rhythm Control Therapy in Patients With Atrial Fibrillation and a High Comorbidity Burden in Large Real-World Cohorts.
    Dickow J; Kany S; Roth Cardoso V; Ellinor PT; Gkoutos GV; Van Houten HK; Kirchhof P; Metzner A; Noseworthy PA; Yao X; Rillig A
    Circ Arrhythm Electrophysiol; 2023 May; 16(5):e011585. PubMed ID: 36942567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study.
    Kim D; Yang PS; You SC; Sung JH; Jang E; Yu HT; Kim TH; Pak HN; Lee MH; Lip GYH; Joung B
    BMJ; 2021 May; 373():n991. PubMed ID: 33975876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial.
    Inzucchi SE; Claggett BL; Vaduganathan M; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Verma S; Han Y; Kerr Saraiva JF; Bengtsson O; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    Lancet Diabetes Endocrinol; 2022 Dec; 10(12):869-881. PubMed ID: 36372069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quarterly versus annual ECG screening for atrial fibrillation in older Chinese individuals (AF-CATCH): a prospective, randomised controlled trial.
    Zhang W; Chen Y; Miao CY; Huang QF; Sheng CS; Shao S; Wang D; Xu SK; Lei L; Zhang D; Chen YL; Hu LX; Xia JH; Ye XF; Cheng YB; Wang Y; Guo QH; Li Y; Lowres N; Freedman B; Wang JG;
    Lancet Healthy Longev; 2021 Aug; 2(8):e470-e478. PubMed ID: 36097996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rate versus rhythm control for atrial fibrillation: from AFFIRM to EAST-AFNET 4 - a paradigm shift.
    Roman S; Patel K; Hana D; Guice KC; Patel J; Stadnick C; Basta A; Khouzam RN
    Future Cardiol; 2022 Apr; 18(4):354-353. PubMed ID: 35255732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial.
    Stiell IG; Sivilotti MLA; Taljaard M; Birnie D; Vadeboncoeur A; Hohl CM; McRae AD; Rowe BH; Brison RJ; Thiruganasambandamoorthy V; Macle L; Borgundvaag B; Morris J; Mercier E; Clement CM; Brinkhurst J; Sheehan C; Brown E; Nemnom MJ; Wells GA; Perry JJ
    Lancet; 2020 Feb; 395(10221):339-349. PubMed ID: 32007169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood-based cardiometabolic phenotypes in atrial fibrillation and their associated risk: EAST-AFNET 4 biomolecule study.
    Fabritz L; Chua W; Cardoso VR; Al-Taie C; Borof K; Suling A; Krause L; Kany S; Magnussen C; Wegscheider K; Breithardt G; Crijns HJGM; Camm AJ; Gkoutos G; Ellinor PT; Goette A; Schotten U; Wienhues-Thelen UH; Zeller T; Schnabel RB; Zapf A; Kirchhof P
    Cardiovasc Res; 2024 Jul; 120(8):855-868. PubMed ID: 38613511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.